Gan & Lee Pharmaceuticals Co Ltd (603087) — Tangible Net Worth Ratio
Gan & Lee Pharmaceuticals Co Ltd (603087) has a Tangible Net Worth Ratio of 82.3% as of March 2026. This metric is calculated by deducting intangible assets (CN¥2.09 Billion) from net assets (CN¥11.83 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore how fast is Gan & Lee Pharmaceuticals Co Ltd growing its equity to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Gan & Lee Pharmaceuticals Co Ltd Tangible Net Worth Ratio (2013–2025)
This chart shows how Gan & Lee Pharmaceuticals Co Ltd's Tangible Net Worth Ratio has changed across 13 annual periods from 2013 to 2025. As of March 2026, the ratio stands at 82.3%, reflecting net assets of CN¥11.83 Billion with intangible assets of CN¥2.09 Billion CNY. For live market cap and overall valuation, see Gan & Lee Pharmaceuticals Co Ltd stock valuation.
Annual Tangible Net Worth Ratio for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2025, covering 13 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore Gan & Lee Pharmaceuticals Co Ltd capital reinvestment ratio to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 83.9% | CN¥11.63 Billion | CN¥1.88 Billion | CN¥12.63 Billion | ▼ -5.4 pp |
| 2024 | 89.2% | CN¥11.05 Billion | CN¥1.19 Billion | CN¥12.04 Billion | ▼ -0.6 pp |
| 2023 | 89.8% | CN¥10.74 Billion | CN¥1.09 Billion | CN¥11.72 Billion | ▲ +0.5 pp |
| 2022 | 89.3% | CN¥9.59 Billion | CN¥1.03 Billion | CN¥10.61 Billion | ▼ -2.1 pp |
| 2021 | 91.4% | CN¥10.17 Billion | CN¥872.49 Million | CN¥10.85 Billion | ▲ +0.0 pp |
| 2020 | 91.4% | CN¥8.94 Billion | CN¥769.62 Million | CN¥9.51 Billion | ▲ +2.2 pp |
| 2019 | 89.2% | CN¥5.47 Billion | CN¥591.33 Million | CN¥6.03 Billion | ▼ -0.9 pp |
| 2018 | 90.1% | CN¥4.27 Billion | CN¥422.84 Million | CN¥4.69 Billion | ▼ -3.5 pp |
| 2017 | 93.6% | CN¥3.34 Billion | CN¥214.49 Million | CN¥3.74 Billion | ▲ +1.1 pp |
| 2016 | 92.5% | CN¥2.26 Billion | CN¥170.05 Million | CN¥2.60 Billion | ▲ +3.9 pp |
| 2015 | 88.6% | CN¥1.49 Billion | CN¥169.25 Million | CN¥1.81 Billion | ▲ +5.0 pp |
| 2014 | 83.6% | CN¥1.04 Billion | CN¥170.05 Million | CN¥1.20 Billion | ▲ +6.5 pp |
| 2013 | 77.1% | CN¥733.22 Million | CN¥167.76 Million | CN¥832.55 Million | — |